{
    "clinical_study": {
        "@rank": "139616", 
        "arm_group": {
            "arm_group_label": "PRT062070", 
            "arm_group_type": "Experimental", 
            "description": "PRT062070 dose escalation study"
        }, 
        "brief_summary": {
            "textblock": "This study will identify the highest dose, and assess the safety, of PRT062070 that may be\n      given in patients with relapsed/refractory chronic lymphocytic leukemia or non-hodgkin\n      lymphoma"
        }, 
        "brief_title": "Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma", 
        "condition": [
            "Chronic Lymphocytic Leukemia (CLL)", 
            "Small Lymphocytic Lymphoma (SLL)", 
            "B-cell Non Hodgkin Lymphoma (NHL)"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphoma, B-Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient must have a diagnosis of CLL/SLL or B-cell Non-Hodgkin lymphoma (diffuse\n             large B-cell lymphoma [DLBCL], follicular lymphoma [FL], mantle cell lymphoma [MCL],\n             MALT lymphoma, marginal zone lymphoma [MZ], lymphoplasmacytic lymphoma)\n\n          -  Patient must be 18 years or older, of either sex, and of any race.\n\n          -  Diagnosis of CLL/SLL or B-cell Non-Hodgkin lymphoma (diffuse large B-cell lymphoma\n             [DLBCL], follicular lymphoma [FL], mantle cell lymphoma [MCL], MALT lymphoma,\n             marginal zone lymphoma [MZ], lymphoplasmacytic lymphoma)\n\n          -  Progression on at least one prior treatment regimen and no standard therapy exists\n\n          -  ECOG Performance Score of 0 or 1.\n\n          -  18 years or older, of either sex, and of any race.\n\n          -  Adequate hematologic, renal and hepatic function\n\n        Exclusion Criteria:\n\n          -  Prior allogeneic stem cell transplant\n\n          -  Known lymphomatous involvement of the central nervous system (CNS).\n\n          -  Investigational therapy within 30 days or 5 half-lives\n\n          -  Known HIV, hepatitis B or hepatitis C infection or is known to be a carrier of\n             hepatitis B or C.\n\n          -  Receiving systemic steroids at doses greater than the equivalent of prednisone, 20 mg\n             daily\n\n          -  Female and is breast-feeding, pregnant or intends to become pregnant."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01994382", 
            "org_study_id": "13-601"
        }, 
        "intervention": {
            "arm_group_label": "PRT062070", 
            "description": "PRT062070 oral pill", 
            "intervention_name": "PRT062070", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Leukemia", 
            "Lymphocytic", 
            "Chronic", 
            "B Cell"
        ], 
        "lastchanged_date": "November 19, 2013", 
        "location": [
            {
                "contact": {
                    "email": "pedigo@scresearch.net", 
                    "last_name": "Heather Pedigo", 
                    "phone": "615-329-7432"
                }, 
                "facility": {
                    "address": {
                        "city": "Sarasota", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34232"
                    }, 
                    "name": "Florida Cancer Specialists/Sarah Cannon Research Institute"
                }, 
                "investigator": {
                    "last_name": "Manish Patel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Heather.pedigo@scresearch.net", 
                    "last_name": "Heather Pedigo"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Tennessee Oncology/Sarah Cannon Research Insitute"
                }, 
                "investigator": {
                    "last_name": "Ian Flinn, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Open-Label, Multi-Dose, Dose Escalation Study Of PRT062070 In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Or B-Cell Non Hodgkin Lymphoma (NHL)", 
        "overall_official": {
            "affiliation": "Portola Pharmaceuticals", 
            "last_name": "Sandra Russell", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Maximum tolerated dose (MTD) of PRT062070 in patients with relapsed/refractory CLL, SLL or B-cell NHL.", 
            "safety_issue": "No", 
            "time_frame": "Approximately 84 days (baseline to end of treatment)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01994382"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Frequency and severity of dose limiting toxicity (as classified by Common Terminology Criteria for Adverse Events (CTCAEv4) by dose level.", 
                "safety_issue": "No", 
                "time_frame": "Approximately 114 days (baseline to 30 days post last treatment)"
            }, 
            {
                "measure": "Peak plasma concentration (Cmax) and area under the plasma concentration versus time curve (AUC) of PRT602070.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to day 22"
            }
        ], 
        "source": "Portola Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Portola Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}